Cargando…

Degree of stemness predicts micro-environmental response and clinical outcomes of diffuse large B-cell lymphoma and identifies a potential targeted therapy

Some cells within a diffuse large B-cell lymphoma (DLBCL) have the genotype of a stem cell, the proportion of which is termed degree of stemness. We interrogated correlations between the degree of stemness with immune and stromal cell scores and clinical outcomes in persons with DLBCL. We evaluated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Fang, Li, Huan, Li, Lei, Gale, Robert Peter, Song, Yuanbin, Chen, Shuiqin, Liang, Yang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9678919/ https://www.ncbi.nlm.nih.gov/pubmed/36426371 http://dx.doi.org/10.3389/fimmu.2022.1012242

Ejemplares similares

Oncogenic Mutations and Tumor Microenvironment Alterations of Older Patients With Diffuse Large B-Cell Lymphoma
por: Zhu, Yue, et al.
Publicado: (2022)

Zanubrutinib plus salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma
por: Yuan, Xianggui, et al.
Publicado: (2022)

The causal effect of inflammatory bowel disease on diffuse large B-cell lymphoma: two-sample Mendelian randomization study
por: Lu, Chuanyang, et al.
Publicado: (2023)

CD19-Targeted Immunotherapies for Diffuse Large B-Cell Lymphoma
por: Gambella, Massimiliano, et al.
Publicado: (2022)

Aberrantly Activated APOBEC3B Is Associated With Mutant p53-Driven Refractory/Relapsed Diffuse Large B-Cell Lymphoma
por: Zhang, Xuzhao, et al.
Publicado: (2022)

Nonclassical Monocytes Are Prone to Migrate Into Tumor in Diffuse Large B-Cell Lymphoma
por: Le Gallou, Simon, et al.
Publicado: (2021)

Efficacy of chimeric antigen receptor T cell therapy and autologous stem cell transplant in relapsed or refractory diffuse large B-cell lymphoma: A systematic review
por: Tian, Linyan, et al.
Publicado: (2023)

Integration analysis of tumor metagenome and peripheral immunity data of diffuse large-B cell lymphoma
por: Zhang, Yu, et al.
Publicado: (2023)

Editorial: Novel treatments for diffuse large B-cell lymphoma: The post-CART era
por: Mussetti, Alberto, et al.
Publicado: (2022)

Exploring the molecular mechanisms and shared gene signatures between rheumatoid arthritis and diffuse large B cell lymphoma
por: Li, Haoguang, et al.
Publicado: (2022)

Risk of HBV reactivation in relapsed or refractory diffuse large B-cell lymphoma patients receiving Bruton tyrosine kinase inhibitors therapy
por: Ni, Ying, et al.
Publicado: (2022)

Low GILT Expression is Associated with Poor Patient Survival in Diffuse Large B-Cell Lymphoma
por: Phipps-Yonas, Hannah, et al.
Publicado: (2013)

International Prognostic Index-Based Immune Prognostic Model for Diffuse Large B-Cell Lymphoma
por: Mu, Shidai, et al.
Publicado: (2021)

Role of Bispecific Antibodies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the CART Era
por: González Barca, Eva
Publicado: (2022)

A 9-LncRNA Signature for Predicting Prognosis and Immune Response in Diffuse Large B-Cell Lymphoma
por: Wang, Xiaoxuan, et al.
Publicado: (2022)

Novel Immune-Based treatments for Diffuse Large B-Cell Lymphoma: The Post-CAR T Cell Era
por: Atallah-Yunes, Suheil Albert, et al.
Publicado: (2022)

Identification of lactate regulation pattern on tumor immune infiltration, therapy response, and DNA methylation in diffuse large B-cell lymphoma
por: Wang, Jinghua, et al.
Publicado: (2023)

Comparison of first-line treatments for elderly patients with diffuse large B-cell lymphoma: A systematic review and network meta-analysis
por: Wang, Yangyang, et al.
Publicado: (2023)

T Cell Defects: New Insights Into the Primary Resistance Factor to CD19/CD22 Cocktail CAR T-Cell Immunotherapy in Diffuse Large B-Cell Lymphoma
por: Wang, Jiachen, et al.
Publicado: (2022)

Sinonasal diffuse large B-cell lymphoma in a patient with Wiskott–Aldrich syndrome: A case report and literature review
por: Sun, Xiwen, et al.
Publicado: (2023)

Decitabine-primed tandem CD19/CD22 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma patients
por: Qu, Changju, et al.
Publicado: (2022)

The gut microbiota correlate with the disease characteristics and immune status of patients with untreated diffuse large B-cell lymphoma
por: Lin, Zhouning, et al.
Publicado: (2023)

EBF1, MYO6 and CALR expression levels predict therapeutic response in diffuse large B-cell lymphomas
por: Turdo, Alice, et al.
Publicado: (2023)

Prognostic value of prelymphodepletion absolute lymphocyte counts in relapsed/refractory diffuse large B-cell lymphoma patients treated with chimeric antigen receptor T cells
por: Lu, Yanyan, et al.
Publicado: (2023)

Diffuse large B-cell lymphoma microenvironment displays a predominant macrophage infiltrate marked by a strong inflammatory signature
por: Serna, Leyre, et al.
Publicado: (2023)

Screening and identification of differentially expressed microRNAs in diffuse large B-cell lymphoma based on microRNA microarray
por: Gao, Hai-Xia, et al.
Publicado: (2021)

CAR T-Cell Therapy Predictive Response Markers in Diffuse Large B-Cell Lymphoma and Therapeutic Options After CART19 Failure
por: Caballero, Ana Carolina, et al.
Publicado: (2022)

Cord blood-derived CD19-specific chimeric antigen receptor T cells: an off-the-shelf promising therapeutic option for treatment of diffuse large B-cell lymphoma
por: Yu, Tiantian, et al.
Publicado: (2023)

Case Report: Dual Inhibition of HDAC and BTK for Diffuse Large B-Cell Lymphoma After Failure to CD19-Targeted CAR-T Therapy
por: Zhu, Weiguo, et al.
Publicado: (2022)

MicroRNA-155 Downregulation Promotes Cell Cycle Arrest and Apoptosis in Diffuse Large B-Cell Lymphoma
por: Zhu, Fu-qiang, et al.
Publicado: (2016)

Role of microRNAs and microRNA machinery in the pathogenesis of diffuse large B-cell lymphoma
por: Caramuta, S, et al.
Publicado: (2013)

Stem cell characteristics promote aggressiveness of diffuse large B-cell lymphoma
por: Chang, Kung-Chao, et al.
Publicado: (2020)

Case Report: Combined Intravenous Infusion and Local Injection of CAR-T Cells Induced Remission in a Relapsed Diffuse Large B-Cell Lymphoma Patient
por: Hu, Linhui, et al.
Publicado: (2021)

The frequency of differentiated CD3(+)CD27(-)CD28(-) T cells predicts response to CART cell therapy in diffuse large B-cell lymphoma
por: Worel, Nina, et al.
Publicado: (2023)

Impact of initial chemotherapy cycles and clinical characteristics on outcomes for HIV-associated diffuse large B cell lymphoma patients: The Central and Western China AIDS Lymphoma League 001 study (CALL-001 study)
por: Wang, Chaoyu, et al.
Publicado: (2023)

MicroRNA and gene networks in human diffuse large B-cell lymphoma
por: WANG, KUNHAO, et al.
Publicado: (2014)

Clinicopathologic implication of microRNA-197 in diffuse large B cell lymphoma
por: Yang, Jeong Mi, et al.
Publicado: (2018)

Systematic Review of the Potential of MicroRNAs in Diffuse Large B Cell Lymphoma
por: Larrabeiti-Etxebarria, Ane, et al.
Publicado: (2019)

Surgery and Chemotherapy versus Chemotherapy Only in Older Persons with Primary Intestinal Diffuse Large B-Cell Lymphoma
por: Zhang, Limei, et al.
Publicado: (2021)

New agents and regimens for diffuse large B cell lymphoma
por: Wang, Liang, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_rjcmp5h8jm4r2dpqm9psfb578l